S07-1066

• Description :

  S07-1066 is an aldo-keto reductase 1C3 (AKR1C3) inhibitor, synergizing doxorubicin (DOX) cytotoxicity. S07-1066 selectively blocks AKR1C3-mediated reduction of DOX, and reverses the DOX resistance in overexpressing AKR1C3 cells[1].

• UNSPSC :

  12352005

• Target :

  17β-HSD

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/s07-1066.html

• Concentration :

  10mM

• Purity :

  99.48

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  ClC1=CC(Cl)=CC(C2=CC=C(C3(C(O)=O)CC3)C=C2F)=C1

• Molecular Formula :

  C16H11Cl2FO2

• Molecular Weight :

  325.16

• References & Citations :

  [1]He S, et al. Development of Biaryl-Containing Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors for Reversing AKR1C3-Mediated Drug Resistance in Cancer Treatment. J Med Chem. 2023 Jul 6.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [876625-29-5]